Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
Bhatia A, Preiss AJ, Xiao X, Brannock MD, Alexander GC, Chew RF, Davis H, Fitzgerald M, Hill E, Kelly EP, Mehta HB, Madlock-Brown C, Wilkins KJ, Chute CG, Haendel M, Moffitt R, Pfaff ER; N3C Consortium.
Bhatia A, et al.
PLoS Med. 2025 Jan 17;22(1):e1004493. doi: 10.1371/journal.pmed.1004493. eCollection 2025 Jan.
PLoS Med. 2025.
PMID: 39823513
Free PMC article.
Millions of treatment courses have been prescribed in the United States alone. Paxlovid was highly effective at preventing hospitalization and death in clinical trials. ...The real-world effectiveness of Paxlovid remains uncertain, and it is unknown whether its effect is h …
Millions of treatment courses have been prescribed in the United States alone. Paxlovid was highly effective at preventing hospitaliz …